Brooksby to be new ABPI president
pharmafile | December 8, 2005 | News story | Sales and Marketing |
Nigel Brooksby, Sanofi-Aventis UK's managing director has been named as the ABPI's next president.
Brooksby will take over from the current ABPI president, Vincent Lawton, of Merck Sharpe & Dohme, in April next year, and will serve for two years.
Brooksby will work alongside ABPI director general Richard Barker in promoting the interests of the UK pharmaceutical industry in its domestic market and within a European context.
"With health services across Europe facing difficult times, it is essential that the pharmaceutical industry works in close co-operation with the government to ensure patients get the best possible treatment," said Brooksby.
Formerly head of Sanofi-Synthelabo in the UK, Brooksby oversaw its merger with Aventis in 2004 and was appointed the managing director of the new company, with responsibility for 3,200 staff.
He is a member of the ABPI's board of management and is chairman of its Commercial Affairs Group.
"Health provision is a complex interaction involving patients, doctors, hospitals, clinics, medicines and other therapies," Brooksby added.
"The pharmaceutical industry must work in partnership with all those involved – especially patients – to ensure that the treatment achieves the best, most appropriate for the individual concerned.
"With new Government priorities, the modernisation of the NHS, and developments in innovative medicines, we have to break down communication barriers to ensure that the voice of all those taking part in the provision of healthcare is heard."
The ABPI will face a number of difficult issues in 2006, including an inquiry into the UK's medicines pricing system by the Office of Fair Trading, which could recommend the tearing up of the current profit control system the PPRS.
Related articles:
Stricter new UK industry code of practice launched
Wednesday, November 16, 2005
